More about

Chronic Total Occlusion

News
October 08, 2020
1 min read
Save

Decline in radiation during CTO PCI could reflect improvements in X-ray systems

Radiation dose during chronic total occlusion PCI decreased between 2012 and 2020 and may be attributed to the use of newer X-ray systems, according to a research letter published in Circulation: Cardiovascular Interventions.

News
July 16, 2020
2 min read
Save

CABG bests PCI in most patients with chronic total occlusion, multivessel disease

In a retrospective study of patients with chronic total occlusion and multivessel CAD, CABG conferred better long-term outcomes than PCI, according to data presented at the virtual PCR e-Course.

News
May 30, 2020
2 min read
Save

SCAI news: REDUCE-IT, fasting before catheterization, telehealth and more

Healio and Cardiology Today have curated a list of the top news from the virtual Society for Cardiovascular Angiography and Interventions Scientific Sessions.

News
May 22, 2020
2 min read
Save

Success, event rates similar after PCI for in-stent, de novo CTO

PCI for in-stent chronic total occlusion had similar success rates and in-hospital complications compared with PCI for de novo CTO, according to new data.

News
March 30, 2020
6 min read
Save

Ticagrelor monotherapy beneficial in complex PCI, diabetes: New TWILIGHT data

In new findings from the TWILIGHT trial of patients who underwent PCI, switching from dual antiplatelet therapy to ticagrelor monotherapy after 3 months benefited patients who had complex PCI and patients with diabetes.

News
March 20, 2020
2 min read
Save

In CTO PCI, prior CABG may portend poor outcomes

Among patients who underwent chronic total occlusion PCI, those with prior CABG had worse outcomes including higher rates of in-hospital morality, MI and coronary perforation compared with those without prior CABG, according to findings from a meta-analysis on the program at the American College of Cardiology Scientific Session.

News
November 12, 2019
2 min read
Save

DCB shows durable real-world effectiveness at 4 years

LAS VEGAS — In a real-world population with peripheral artery disease, nearly three-quarters of patients treated with a drug-coated balloon were free from clinically driven target lesion revascularization at 4 years, according to new data presented at VIVA 19.

View more